Method of ablating tissue

Information

  • Patent Grant
  • 7794460
  • Patent Number
    7,794,460
  • Date Filed
    Monday, August 11, 2008
    16 years ago
  • Date Issued
    Tuesday, September 14, 2010
    14 years ago
Abstract
An electrocautery device is disclosed. In accordance with one aspect of the invention, the electrocautery electrode/tip is provided with a hollow, conductive tube terminating at its distal end in a ball point type tip. Fluid, preferably conductive fluid, is applied to the proximal end of the hollow electrode/tip, and expelled from the distal end thereof during electrocautery. The ball point distal tip allows the distal tip to be directly applied to the tissue and “rolled” or slid along the tissue. This allows the distal tip to be moved across the tissue without dragging or snagging on the tissue. In addition, the conductive fluid expelled from the distal tip further lubricates the distal tip as it moves across the tissue. If conductive fluid is used, the conductive fluid emanating from the electrode/tip conducts the RF electrocautery energy away from the distal tip so that it is primarily the fluid, rather than the distal tip that actually accomplishes the cauterizing of tissue. That is, the fluid serves as a “virtual” electrocautery electrode. Since it is the fluid, rather than the distal tip that cauterizes, coagulates and ablates, no burns or perforations are made to the tissue, reducing the amount of debris at the site. Also, the flow of fluid through the electrode/tip tends to keep the distal tip clean and cool.
Description
FIELD OF THE INVENTION

This invention relates generally to the field of medical instruments, and more particularly relates to an electrocautery device.


BACKGROUND OF THE INVENTION

Various types of electrocautery devices for incising and cauterizing body tissue are known and used in the medical field. Typically, such devices include a conductive tip or needle which serves as one electrode in an electrical circuit which is completed via a grounding electrode coupled to the patient. Incision of tissue is accomplished by applying a source of electrical energy (most commonly, a radio-frequency generator) to the tip. Upon application of the tip to the tissue, a voltage gradient is created, thereby inducing current flow and related heat generation at the point of contact. With sufficiently high levels of electrical energy, the heat generated is sufficient to cut the tissue and, advantageously, to simultaneously cauterize severed blood vessels.


It is widely recognized in the prior art that the often substantial amount of smoke produced by electrocauterization of tissue is at least unpleasant, and in some cases distracting or even hazardous to the operator and other attending medical personnel. As a result, it has been proposed, and is common, to provide an electrocautery device with smoke-aspirating capabilities, such that the smoke produced from electrocauterization is quickly withdrawn from the area of incision. Smoke aspiration may be accomplished by providing, in the handle of the electrocautery device near the electrocautery tip/electrode, an inlet port to be coupled to a vacuum or suction source. Examples of this are described in U.S. Pat. No. 4,307,720 to Weber, Jr., entitled “Electrocautery Apparatus and Method and Means for Cleaning the Same;” in U.S. Pat. No. 5,242,442 to Hirschfeld, entitled “Smoke Aspirating Electrosurgical Device;” and in U.S. Pat. No. 5,269,781 to Hewell, entitled “Suction Assisted Electrocautery Unit.”


It has also been recognized in the prior art that the accumulation of coagulated blood, tissue rubble, and other debris on the electrode/tip of an electrocautery device can present a problem for the operator, necessitating the periodic cleaning of the tip, e.g., by wiping the tip over sterilized gauze or the like. This is generally regarded as undesirable, since the need to clean the electrode/tip tends to interrupt the incision procedure and increases the risks associated with contamination of the tip or the incision, damage to the tip, injury to the operator, and the like. To address this problem, it has been proposed in the prior art to provide an electrocautery instrument in which the electrode/tip is in slidable engagement with the instrument's handle, such that when the tip is retracted into the hand, any adhering debris automatically scraped off onto the tip of the handle. Such an instrument is proposed in the above-referenced Weber, Jr. '720 patent. While this arrangement may have some benefit, it still may be necessary to wipe off the tip of the handle once the tip is retracted. It is believed that a more direct and effective approach to the problem would be to reduce the amount of debris created during the electrocautery process, thereby eliminating or at least reducing the need to clean the electrode/tip.


Atrial fibrillation is the condition where the normal rhythmic contractions of the heart are replaced by rapid irregular twitchings of the muscular heart wall. At least 1 million people in the U.S. suffer from atrial fibrillation. There are at least three detrimental side effects that occur during atrial fibrillation: a rapid irregular heartbeat; impaired cardiac hemodynamics due to a loss of AV synchrony; and an increased vulnerability to thromboembolism. Surgical Treatment of Cardiac Arrhythmias, by Willis Hurst, pg. 867.


The typical treatment for atrial fibrillation has been to give the patient drugs. For most patients with atrial fibrillation, this therapy has been only moderately effective and has typically produced undesirable side effects.


In view of the problems with drug therapy to treat atrial fibrillation, it has been recognized as desirable to find a surgical treatment that would permanently cure atrial fibrillation. Cardiovascular Device Update, July 1995, pg. 1. Although radiofrequency catheter ablation (RFCA) has proven to be a safe and effective way of treating the most benign causes of supraventricular tachycardia (SVT), such as Wolff-Parkinson-White and AV nodal re-entry tachycardia, using ablation to treat atrial fibrillation has proven to be challenging. Id.


The so called “maze” procedure has been developed to treat atrial fibrillation. In the “maze” procedure, incisions are made into the right and left atria via an open chest surgical procedure. These incisions are located to interrupt all the potential re-entry circuit patterns that could occur in the atria and cause atrial fibrillation. The clinical success with the “maze” procedure has been good.


A problem with the “maze” procedure is that it requires open chest surgery which is undesirable. It has been recognized that it would be desirable to duplicate the “maze” procedure with ablation. Id. at pg. 3. This would allow the possibility of performing a “maze”-like procedure thorascopically. However, it has also been recognized that current ablation technology has not developed to allow the “maze” procedure to be duplicated with ablation. Id.


A problem with prior art ablation has been that the ablating tip, if left in contact with a piece of tissue for too long, will burn through and perforate the tissue. In many applications, it has proven difficult to balance leaving an ablating tip in position on a piece of tissue for a sufficient time to allow the tissue to be ablated but not leave it in place for a length of time to burn through and thereby perforate the tissue.


Another problem with prior art ablation devices is that if the ablating tips are left in contact with the tissue too long, the tip “sticks” to the tissue being ablated. In removing the tip, large portions of tissue are often removed attached to the tip. This is not only a result to be avoided because of the tissue damage, but it is time consuming and irritating to the physician. These are clearly problems to be avoided.


SUMMARY OF THE INVENTION

In view of the foregoing considerations, the present invention is directed to an improved electrocautery instrument.


In accordance with one aspect of the invention, the electrocautery electrode/tip is implemented with a hollow, conductive tube terminating at its distal end in a ball point type tip. Conductive fluid is applied to the proximal end of the hollow electrode/tip, and expelled from the distal end thereof during electrocautery. The ball point distal tip allows the distal tip to be directly applied to the tissue and “rolled” or slid along the tissue. This allows the distal tip to be moved across the tissue without dragging or snagging on the tissue. In addition, the conductive fluid expelled from the distal tip further lubricates the distal tip as it moves across the tissue.


In accordance with another aspect of the invention, the conductive fluid emanating from the electrode/tip conducts the RF electrocautery energy away from the distal tip so that it is primarily the fluid, rather than the distal tip that actually accomplishes the cauterizing of tissue. That is, the fluid serves as a “virtual” electrocautery electrode. Since it is the fluid, rather than the distal tip that cauterizes, coagulates and ablates, no burns or perforations are made to the tissue, reducing the amount of debris at the site of ablation. Also, the flow of fluid through the electrode/tip tends to keep the distal tip clean and cool.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other aspects of the present invention may perhaps be best appreciated with reference to a detailed description of a specific embodiment of the invention, when read in conjunction with the accompanying drawings, wherein:



FIG. 1 is a perspective view of an electrocautery instrument in accordance with one embodiment of the invention;



FIG. 2 is a perspective view of the invention separated from the handle.



FIG. 3 is an enlarged perspective view of the distal end of the electrocautery device of FIG. 1 showing the electrode/tip.



FIG. 4 is a cross-sectional view of the electrode/tip of the device of FIGS. 1, 2 and 3.



FIG. 5 is a cross-sectional view of another embodiment of electrode/tip of the invention.



FIG. 6 is a perspective view of an electrocautery instrument in accordance with one embodiment of the invention.





DETAILED DESCRIPTION OF A SPECIFIC EMBODIMENT OF THE INVENTION

Referring to FIG. 1 and FIG. 6, there is shown a perspective view of a fluid-assisted electrocautery device 10 in accordance with one embodiment of the invention. Electrocautery device 10 comprises a handle 12 and an electrocautery electrode/tip 14. Handle 12 is preferably made of a sterilizable, rigid, and non-conductive material, such as nylon or the like. Electrode/tip 14 is attached to handle 12.


In accordance with one aspect of the invention, electrode/tip 14 is preferably implemented using a hollow cylindrical tube 16 with a “ball point” at its distal end, as shown in the greatly enlarged perspective and cross-sectional views of FIGS. 3 and 4, respectively. As can be seen, a ball 18 is retained in a cavity formed by crimping metal tube 16 around ball 18. Both ball 18 and tube 16 are preferably made of an electrically conductive metal such as stainless steel. Tube 16 is crimped both proximal and distal to ball 18 at 20 and 22, respectively.


Ball 18 may have any diameter but balls 18 having diameters of from about 1 to about 5 mm have been found to be particularly effective for ablating. Tube 16 must have a diameter corresponding to the diameter of ball 18 as explained herein. Consequently, tube 16 preferably has an internal diameter, particularly at its distal end, of from about 1 to about 5 mm.


Crimping may be accomplished by a number of techniques including but not limited to placing a series of “crimps” 24 around the periphery of tube 16 that are directed toward the interior 26 of tube 16. In addition, the distal end 28 of tube 16 is “crimped” by rounding it toward the interior 26 of tube 16. In this way, ball 18 is retained between the “crimps” 24 and the rounded distal end 28. Crimping should be done so that a portion of ball 18 extends distally beyond distal end 28.


Tube 16 preferably has in interior 26 diameter slightly larger than the diameter of ball 18. In any case, after crimping as described above, the portion of tube 16 surrounding ball 18 should have a slightly larger internal diameter than ball 18. This allows ball 18 to freely rotate between crimps 24 and distal end 28 and still be retained at electrode/tip 14.


An electrical insulator 30 preferably surrounds tube 16 along substantially its entire length, terminating a short distance from distal end 28. Insulator 30 prevents accidental cautery from taking place at locations other than electrode/tip 14 if tube 16 should inadvertently contact patient tissue during a procedure.


Two connections are made to electrocautery device 10. One terminal (e.g., positive) of a radio-frequency (RF) generator (not shown in FIG. 1) is electrically coupled to electrode/tip 14 via a wire 32 attached to tube 16. Contact between ball 18 and tube 16, as will be described in more detail hereafter, provides electrical potential to ball 18.


A source of fluid to be expelled from electrode/tip 14 is coupled to tube 16 via a flexible input line 34. Input line 34 is preferably a tube or hose. Conductive fluid is provided under pressure through tube 16 to the electrode/tip 14. The conductive fluid is introduced to tube 16, as shown in FIG. 2, through input line 34 that is connected to a fluid inlet port 36 on tube 16. Conductive fluid passes from inlet line 34 through fluid inlet port 36 into tube 16 and is communicated along the length of tube 16 to electrode/tip 14 to be expelled from the distal end thereof. This creates a so-called “virtual electrode” for performing electrocautery.


The infusion of conductive fluid simultaneously with the application of RF energy is discussed in further detail in: U.S. patent application Ser. No. 08/113,441 entitled “Method and Apparatus for R-F Ablation,” filed on Aug. 27, 1993 in the name of Peter M. J. Mulier and Michael F. Hoey, in U.S. patent application Ser. No. 08/303,246, entitled “Method of Apparatus for RF Ablation,” filed on Sep. 8, 1994 in the name of Peter M. J. Mulier; in U.S. patent application Ser. No. 08/302,304 entitled “Method and Apparatus for RF Ablation,” filed in the name of Peter M. J. Mulier and Michael F. Hoey on Sep. 8, 1994 and in U.S. patent application Ser. No. 08/393,082 entitled “Fluid Assisted Electrocautery Device”, filed in the name of Peter M. J. Mulier and Michael F. Hoey on Feb. 22, 1995. The foregoing '441, '246, '304 and '082 applications (hereinafter collectively referred to as “the RF ablation applications”) are each commonly assigned to the assignee of the present invention, and incorporated by reference herein in their respective entireties.


As described in the RF ablation patent applications, the infusion of conductive fluid into the area of application of RF energy creates a “virtual electrode,” the size and shape of which can be controllably modified, and which can be rendered more or less conductive, thereby modifying the spread of RF energy. By varying such factors as the RF energy and duration, the rate of infusion of conductive liquid, and the conductivity of the infused solution, the size, shape, and intensity of the “virtual electrode”—i.e., the intensity of thermal production in the area, can be controlled. In the case of the electrocautery device in accordance with the present invention, application of the conductive solution during the application of RF energy further assists by preventing overheating of the electrode/tip, extending the point at which burning or charring of tissue would otherwise normally occur. To enhance this effect, it is contemplated that the solution being infused may first be cooled.


Conductive solutions believed to be suitable for establishing the virtual electrode include saline, saturated saline, and Ringer's solution, among others. Regarding the source of conductive fluid, it is contemplated that a conventional pump may be coupled to input line 34. Alternatively, it is contemplated that a small, pre-pressurized canister 35 of conductive solution may be used, such that no pump is required as shown in FIG. 6. In one embodiment, handle 12 may be configured to receive such a pressurized canister 35 therein, eliminating the need for input line 34.


In addition, a dye may be mixed with the conductive fluid to make the fluid more visible during the procedure using the device 10. Examples of such a dye include, but are not limited to methylene blue.


It is desirable to provide the conductive fluid to electrode/tip 14 under pressure that is controlled. In particular, it is important not to have a flow rate that allows conductive fluid to flow excessively out of the distal end 28 of electrode/tip 14.


Excessive fluid flow has been shown to spread the electrical current density over a large area of the tissue thereby minimizing, and in some cases preventing, the ablation effect.


In use, electrical potential is applied to tube 16 from a radio-frequency (RF) generator as described above. Since tube 16 is made of an electrically conductive metal, the entire tube 16 will be at an electrical potential determined by the radio-frequency (RF) generator. Conductive fluid is supplied under pressure to the device 10 so that the conductive fluid is expelled from electrode/tip 14 around ball 18.


The user of electrocautery device 10 places electrode/tip 14 at an area to ablate and moves the electrode/tip 14 across the tissue by ball 18 contacting the tissue. Ball 18 may either roll or be slid across the tissue. The fluid expelled from the distal end 28 lubricates the tissue and facilitates the movement of ball 18 across the tissue regardless of whether ball 18 rolls or slides across the tissue.


In vitro experiments have shown the following: The larger the diameter of ball 18, the wider and deeper the ablation “track” created on the tissue; Moving the electrode/tip 14 slowly across the tissue creates deeper lesions than if electrode/tip 14 is moved quickly; and the flow rate of conductive fluid through device 10 and out of electrode/tip 14 should be adequate to wet and lubricate the surface of the tissue but should not be so high as to spread across the tissue and spread the electrical current density necessary to perform the ablation. As examples of desirable flow rates of conductive fluid through the device 10, with a radio-frequency (RF) generator at 50 Watts, a flow rate of about between 0.5 and 2 cc/minute was shown to be adequate and with a radio-frequency (RF) generator at 25 Watts, a flow rate of about between 1 and 2 cc/minute was shown to be adequate. Other flow rates in these power ranges or these or different flow rates for other power settings may also be used as will be clear with practice using the invention. The examples given above being given for the purpose of illustration and are not intended to be limiting.


The device 10 may be particularly used in connection with the so called “maze” procedure described above to ablate an area of the heart to interrupt all the potential re-entry circuit patterns that could occur in the atria and cause atrial fibrillation. The device 10 could also be used advantageously to remove hemorrhoids or varicose veins or stop esophageal bleeding to name but a few possible uses. The device removes the risk of perforation commonly found with other types of cautery, is easy to “write” with and allows deep and wide penetration and subsequently ablation.


Because of its similarity to a ball point pen, the invention provides an electrocautery device 10 that is easy to “write” with. That is, it is easy to move the distal elected/tip 14 across the tissue to be ablated because the ball 18 rolls across the tissue. In addition, by expelling fluid from electrode/tip 14, ball 18 also slides across the tissue being ablated.


Although in the embodiment of FIG. 1, wire 32 and input line 34 are depicted separately, it is contemplated that these connections to device 10 may be consolidated into a single line having a fluid-conducting lumen therein for input of conductive solution alongside an insulated electrical conductor.


Various alternate configurations of electrode/tip 14 are also contemplated. In one embodiment shown in FIG. 5, ball 18 is enclosed within tube 16 at the distal end 28 of tube 16. However, instead of having crimps 24 proximal to ball 18, a block 38 is placed proximal to ball 18 within tube 16. Block 38 preferably has a central lumen 40 exiting from its proximal to its distal end to allow fluid in the interior of tube 16 to pass to ball 18 where it may be expelled from distal end 28. In all other ways, this embodiment is identical to the preferred embodiment described above.


Ball 18 may also be made of a porous, electrically conductive material. In this embodiment, the porous nature of ball 18 allows fluid to not only pass around ball 18 to be expelled from distal end 28, but also allows fluid to pass through ball 18 to be expelled.


In an alternate embodiment, ball 18 may be replaced with a non-spherical contact element such as an electrically conductive elongated plug. In this embodiment, the plug would still be retained in tube 16 at the distal end 28 of tube 16 so that fluid can pass around the plug to expelled from the distal end 28. The plug would be retained by any means described above including, but not limited to, crimps 24 and the rounded distal end 28. However, because the plug is not spherical, the plug can not roll as it is moved in contact across the tissue to be ablated. Instead, the plug will slide across the tissue. In this embodiment, the plug may also be made of an electrically conductive porous material.


Although the invention has been described in connection with using a conductive fluid to create a virtual electrode for electrode/tip 14, it is clear that many of the advantages of the invention such as the smooth flow of electrode/tip 14 will also be produced with the conductive fluid replaced with non-conducting fluid such as pure water. Therefore, it is also within the scope of the invention to include the use of a non-conducting fluid.


In addition, if desired, a suction tube 42 and suction line 44 may be added to the device 10 to allow smoke or excess fluid to be removed from the surgical field. Such a suction tube 42 is described in the '082 application described above, the teachings of which have been incorporated by reference herein.


Further, tube 16 may be made of an electrically insulating material except for a portion at its distal end that comes in contact with ball 14. This portion of tube 16 that comes in contact with ball 14 should be electrically conducting. In this embodiment, wire 24 extends to this electrically conducting portion of tube 16.


From the foregoing detailed description of a specific embodiment of the invention, it should be apparent that a method and apparatus for performing fluid-assisted electrocautery of body tissue has been disclosed, wherein fluid delivered out of a hollow electrocautery electrode/tip creates a virtual electrode which incises and cauterizes the tissue.


Although a specific embodiment of the invention has been described herein, this has been done solely for the purposes of illustrating various aspects of the invention, and is not intended to be limiting with respect to the scope of the invention. It is contemplated that various substitutions, alterations, and/or modifications, including but not limited to those specifically discussed herein, may be made to the disclosed embodiment without departing from the spirit and scope of the invention as defined in the appended claims, which follow.

Claims
  • 1. A method of creating an ablation lesion in tissue of a patient for treating atrial fibrillation, the method comprising: creating an opening in the patient's chest;inserting a distal portion of a tissue ablation device through the opening in the patient's chest, the distal portion comprising a tissue ablating element;positioning the ablating element adjacent tissue to be ablated;delivering a pressurized fluid from a fluid source through a device lumen to the ablating element to cool the ablating element while ablating tissue; and,forming an ablation lesion in the tissue with the ablating element without burning or charring the tissue while continuing the delivery of fluid to cool the ablating element, wherein the ablation lesion interrupts potential re-entry circuit patterns that could occur in atrial tissue and cause atrial fibrillation and wherein the ablation lesion replaces at least one surgical incision of a Maze procedure for treating atrial fibrillation.
  • 2. The method of claim 1, wherein the ablation device further comprises a suction tube.
  • 3. The method of claim 2, wherein the ablation device further comprises a suction hose coupled to a proximal end of the suction tube and adapted to be coupled to a suction pump for removing a substance through the distal end of the suction tube.
  • 4. The method of claim 2, further comprising the step of applying suction to a suction tube to remove a substance.
  • 5. The method of claim 1, wherein the ablating element is located at a distal tip of the device.
  • 6. The method of claim 1, wherein the fluid is delivered under pressure that is controlled.
  • 7. The method of claim 1, wherein the pressurized fluid is delivered through a smaller first device lumen into a larger second device lumen.
  • 8. The method of claim 7, wherein the ablating element comprises the second lumen.
  • 9. The method of claim 1, wherein the pressurized fluid is delivered through an orifice having a smaller internal lumen diameter into a portion of the ablating element having a larger internal lumen diameter.
  • 10. The method of claim 1, wherein the fluid contacts the ablating element to cool the ablating element.
  • 11. The method of claim 1, further comprising contacting tissue to be ablated with the ablating element.
  • 12. The method of claim 1, wherein the fluid is cooled before contacting the ablating element.
  • 13. The method of claim 1, wherein the fluid is cooled before delivery through the device lumen.
  • 14. The method of claim 1, wherein delivering fluid through the lumen includes delivering fluid via a pump.
  • 15. The method of claim 1, wherein the fluid source comprises a pump.
  • 16. The method of claim 1, wherein the fluid source comprises an input line and a pump.
  • 17. The method of claim 1, wherein the lumen is connectable to the source of fluid with a fluid input line.
  • 18. The method of claim 1, further comprising a fluid input tube in fluid communication with the lumen.
  • 19. The method of claim 1, wherein the fluid source comprises a canister.
  • 20. The method of claim 19 wherein the canister is pre-pressurized.
  • 21. The method of claim 1, wherein the fluid source comprises a pressurized canister.
  • 22. The method of claim 1, wherein delivering fluid through the lumen includes delivering fluid via a pressurized canister.
  • 23. The method of claim 1, wherein the ablating element comprises a metal.
  • 24. The method of claim 1, wherein an outer axial surface of the ablating element is exposed.
  • 25. The method of claim 1, wherein at least a portion of the ablating element is hollow.
  • 26. The method of claim 1, wherein at least a portion of the ablating element comprises the lumen.
  • 27. The method of claim 1, wherein the device comprises a tubular member.
  • 28. The method of claim 27, wherein the tubular member comprises the lumen.
  • 29. The method of claim 28, wherein the lumen is at least in a portion of the tubular member proximal to the distal end of the tubular member.
  • 30. The method of claim 27, wherein the tubular member comprises the ablating element.
  • 31. The method of claim 27, wherein at least an external portion of the tubular member is insulated.
  • 32. The method of claim 27, wherein the tubular member comprises an insulating material.
  • 33. The method of claim 27, wherein the tubular member comprises a rounded distal end.
  • 34. The method of claim 1, further comprising sliding the ablating element along a length while forming the ablation lesion.
  • 35. The method of claim 1, further comprising moving the ablating element along a length of the tissue without snagging the tissue while forming the ablation lesion.
  • 36. The method of claim 1, wherein the tissue to be ablated is tissue of the right atria.
  • 37. The method of claim 1, wherein the tissue to be ablated is tissue of the left atria.
  • 38. The method of claim 1, wherein the ablation lesion is created in tissue of the right atria.
  • 39. The method of claim 1, wherein the ablation lesion is created in tissue of the left atria.
  • 40. A method of creating an ablation lesion in atrial tissue of a patient for treating atrial fibrillation, the method comprising: creating an opening in the patient's chest;inserting a distal portion of a tissue ablation device through the opening in the patient's chest, the distal portion comprising a tissue ablating element;manipulating a device handle coupled to the ablating element to manipulate the ablating element to contact atrial tissue to be ablated;delivering a pressurized fluid from a fluid source through a device lumen to the ablating element to cool the ablating element; and,forming an ablation lesion in the tissue with the ablating element without burning or charring the tissue while continuing the delivery of fluid to cool the ablating element, wherein the ablation lesion interrupts potential re-entry circuit patterns that could occur in atrial tissue and cause atrial fibrillation and wherein the ablation lesion replaces at least one surgical incision of a Maze procedure for treating atrial fibrillation.
  • 41. The method of claim 40, wherein the handle comprises the fluid source.
  • 42. The method of claim 40, wherein the handle receives the fluid source.
  • 43. The method of claim 42, wherein the fluid source comprises a canister receivable within the handle.
  • 44. The method of claim 43, wherein a portion of a fluid input tube extends within the handle.
  • 45. The method of claim 40, wherein the ablation device comprises a fluid input tube mounted at the proximal end of the handle and in fluid communication with the device lumen.
  • 46. The method of claim 40, wherein the device comprises a tubular member coupled to the handle, the tubular member comprising the ablating element.
  • 47. The method of claim 46, wherein at least a portion of the tubular member is co-axially disposed within the handle.
  • 48. A method of creating an ablation lesion in atrial tissue of a patient for treating atrial fibrillation, the method comprising: providing an ablation device, the device comprising:an elongated tubular member having a proximal end and a distal end portion, the distal end portion comprising a metal tissue ablating element, the elongated tubular member comprising a lumen extending from the proximal end to the ablating element;a handle coupled to the proximal end of the tubular member;a pressurized fluid source fluidly coupled to the lumen for delivering a fluid to the ablating element to cool the ablating element while ablating tissue, wherein the fluid contacts a portion of the ablating element;an elongated tubular suction member having a proximal end and a distal end, the proximal end coupled to the handle, the distal end of the elongated tubular member extending distally beyond the distal end of the suction tubular member; andan insulative element co-axially disposed over a non-ablating portion of the elongated tubular member;creating an opening in the patient's chest;inserting the ablating element through the opening in the patient's chest;manipulating the handle to cause the ablating element to contact atrial tissue to be ablated;delivering fluid from the fluid source through the device lumen to the ablating element to cool the ablating element; and,forming an ablation lesion in the atrial tissue with the ablating element without burning or charring the tissue while continuing the delivery of fluid to cool the ablating element, wherein the ablation lesion interrupts potential re-entry circuit patterns that could occur in atrial tissue and cause atrial fibrillation and wherein the ablation lesion replaces at least one surgical incision of a Maze procedure for treating atrial fibrillation.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 11/635,166, filed Dec. 7, 2006, now U.S. Pat. No. 7,422,588, which is a continuation of U.S. patent application Ser. No. 11/230,839, filed Sep. 20, 2005, now U.S. Pat. No. 7,166,105, which is a continuation of U.S. patent application Ser. No. 10/883,178, filed Jul. 1, 2004, now U.S. Pat. No. 6,949,098, which is a continuation of U.S. patent application Ser. No. 10/411,921, filed Apr. 11, 2003, now U.S. Pat. No. 6,764,487, which is a continuation of U.S. patent application Ser. No. 09/955,496, filed Sep. 18, 2001, now U.S. Pat. No. 6,585,732, which is a continuation of U.S. patent application Ser. No. 09/580,228, filed May 26, 2000, now U.S. Pat. No. 6,358,248, which is a continuation of U.S. patent application Ser. No. 09/236,034, filed Jan. 22, 1999, now abandoned, which is a continuation of U.S. patent application Ser. No. 08/556,784, filed Nov. 2, 1995, now U.S. Pat. No. 5,897,553, which is a continuation-in-part of U.S. patent application Ser. No. 08/393,082, filed Feb. 22, 1995, now U.S. Pat. No. 6,063,081, which applications are incorporated herein by reference.

US Referenced Citations (527)
Number Name Date Kind
623022 Johnson Apr 1899 A
1735271 Groff Nov 1929 A
2102270 Mortimer Dec 1937 A
2275167 Bierman Mar 1942 A
2888928 Seiger Jun 1959 A
3163166 Brent et al. Dec 1964 A
3736936 Basiulis et al. Jun 1973 A
3807403 Stumpf et al. Apr 1974 A
3823575 Parel Jul 1974 A
3823718 Tromovitch Jul 1974 A
3827436 Stumpf et al. Aug 1974 A
3830239 Stumpf Aug 1974 A
3859986 Okada et al. Jan 1975 A
3862627 Hans, Sr. Jan 1975 A
3886945 Stumpf et al. Jun 1975 A
3901241 Allen Aug 1975 A
3907339 Stumpf et al. Sep 1975 A
3910277 Zimmer Oct 1975 A
3913581 Ritson et al. Oct 1975 A
3924628 Droegemueller et al. Dec 1975 A
4018227 Wallach Apr 1977 A
4022215 Benson May 1977 A
4037590 Dohring et al. Jul 1977 A
4061135 Widran et al. Dec 1977 A
4063560 Thomas et al. Dec 1977 A
4072152 Linehan Feb 1978 A
4074718 Morrison Feb 1978 A
4082096 Benson Apr 1978 A
4207897 Lloyd et al. Jun 1980 A
4248224 Jones Feb 1981 A
4275734 Mitchiner Jun 1981 A
4278090 van Gerven Jul 1981 A
4301802 Poler Nov 1981 A
4307720 Weber, Jr. Dec 1981 A
4326529 Doss et al. Apr 1982 A
4377168 Rzasa et al. Mar 1983 A
4506680 Stokes Mar 1985 A
4519389 Gudkin et al. May 1985 A
4532924 Auth et al. Aug 1985 A
4567890 Ohta et al. Feb 1986 A
4598698 Siegmund Jul 1986 A
4601290 Effron et al. Jul 1986 A
4602628 Allen Jul 1986 A
4641649 Walinsky et al. Feb 1987 A
4664110 Schanzlin May 1987 A
4674498 Stasz Jun 1987 A
4674499 Pao Jun 1987 A
4682596 Bales et al. Jul 1987 A
4736749 Lundback Apr 1988 A
4748979 Hershenson Jun 1988 A
4779611 Grooters et al. Oct 1988 A
4802475 Weshahy Feb 1989 A
4802476 Norenberg et al. Feb 1989 A
4815470 Curtis et al. Mar 1989 A
4832048 Cohen May 1989 A
4850353 Stasz et al. Jul 1989 A
4862890 Stasz et al. Sep 1989 A
4869248 Narula Sep 1989 A
4872346 Kelly-Fry et al. Oct 1989 A
4896671 Cunningham et al. Jan 1990 A
4916922 Mullens Apr 1990 A
4917095 Fry et al. Apr 1990 A
4920982 Goldstein May 1990 A
4931047 Broadwin et al. Jun 1990 A
4932952 Wojciechowicz Jun 1990 A
4936281 Stasz Jun 1990 A
4943290 Rexroth et al. Jul 1990 A
4946460 Merry et al. Aug 1990 A
4966597 Cosman Oct 1990 A
4976711 Parins et al. Dec 1990 A
4977902 Sekino et al. Dec 1990 A
4979948 Geddes et al. Dec 1990 A
4985030 Melzer et al. Jan 1991 A
5007908 Rydell et al. Apr 1991 A
5013312 Parins et al. May 1991 A
5029574 Shimamura et al. Jul 1991 A
5044165 Linner et al. Sep 1991 A
5056517 Fenici Oct 1991 A
5057107 Parins et al. Oct 1991 A
5071419 Rydell et al. Dec 1991 A
5078713 Varney Jan 1992 A
5078717 Parins et al. Jan 1992 A
5080102 Dory Jan 1992 A
5080660 Buelina Jan 1992 A
5083565 Parins Jan 1992 A
5087256 Taylor et al. Feb 1992 A
5098431 Rydell Mar 1992 A
5100388 Behl et al. Mar 1992 A
5108390 Potocky et al. Apr 1992 A
5122137 Lennox Jun 1992 A
5122138 Manwaring Jun 1992 A
5125928 Parins et al. Jun 1992 A
5129396 Rosen et al. Jul 1992 A
5147355 Friedman et al. Sep 1992 A
5150717 Rosen et al. Sep 1992 A
5167659 Ohtomo et al. Dec 1992 A
5171311 Rydell et al. Dec 1992 A
5178133 Pena Jan 1993 A
5178618 Kandarpa Jan 1993 A
5188635 Radtke Feb 1993 A
5190541 Abele et al. Mar 1993 A
5192280 Parins Mar 1993 A
5195959 Smith Mar 1993 A
5197963 Parins Mar 1993 A
5197964 Parins Mar 1993 A
5207674 Hamilton May 1993 A
5215103 Desai Jun 1993 A
5217460 Knoepfler Jun 1993 A
5217860 Fahy et al. Jun 1993 A
5220927 Astrahan et al. Jun 1993 A
5222501 Ideker et al. Jun 1993 A
5224943 Goddard Jul 1993 A
5228923 Hed Jul 1993 A
5230349 Langberg Jul 1993 A
5231995 Desai Aug 1993 A
5232516 Hed Aug 1993 A
5242441 Avitall Sep 1993 A
5242442 Hirshfield Sep 1993 A
5254116 Baust et al. Oct 1993 A
5263493 Avitall Nov 1993 A
5269291 Carter Dec 1993 A
5269781 Hewell, III Dec 1993 A
5275595 Dobak, III Jan 1994 A
5277201 Stern Jan 1994 A
5277696 Hagen Jan 1994 A
5281213 Milder et al. Jan 1994 A
5281215 Milder Jan 1994 A
5281217 Edwards et al. Jan 1994 A
5281218 Imran Jan 1994 A
5282799 Rydell Feb 1994 A
5290286 Parins Mar 1994 A
5295484 Marcus et al. Mar 1994 A
5300087 Knoepfler Apr 1994 A
5309896 Moll et al. May 1994 A
5313943 Houser et al. May 1994 A
5316000 Chapelon et al. May 1994 A
5317878 Bradshaw et al. Jun 1994 A
5318525 West et al. Jun 1994 A
5322520 Milder Jun 1994 A
5323781 Ideker et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5324284 Imran Jun 1994 A
5324286 Fowler Jun 1994 A
5334181 Rubinsky et al. Aug 1994 A
5334193 Nardella Aug 1994 A
5342357 Nardella Aug 1994 A
5348554 Imran et al. Sep 1994 A
5353783 Nakao et al. Oct 1994 A
5354258 Dory Oct 1994 A
5361752 Moll et al. Nov 1994 A
5383876 Nardella Jan 1995 A
5385148 Lesh et al. Jan 1995 A
5395312 Desai Mar 1995 A
5395363 Billings Mar 1995 A
5396887 Imran Mar 1995 A
5397304 Truckai Mar 1995 A
5398683 Edwards et al. Mar 1995 A
5400770 Nakao et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403309 Coleman et al. Apr 1995 A
5403311 Abele et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5423807 Milder Jun 1995 A
5423811 Imran et al. Jun 1995 A
5427119 Swartz et al. Jun 1995 A
5431649 Mulier Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5435308 Gallup et al. Jul 1995 A
5437651 Todd et al. Aug 1995 A
5437662 Nardella Aug 1995 A
5441498 Perkins Aug 1995 A
5443463 Stern et al. Aug 1995 A
5443470 Stern et al. Aug 1995 A
5450843 Moll et al. Sep 1995 A
5452582 Longsworth Sep 1995 A
5452733 Sterman et al. Sep 1995 A
5458596 Lax et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5462521 Brucker et al. Oct 1995 A
5462545 Wang et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5469853 Law et al. Nov 1995 A
5472441 Edwards et al. Dec 1995 A
5472876 Fahy Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5478330 Imran et al. Dec 1995 A
5486193 Bourne et al. Jan 1996 A
5487385 Avitall Jan 1996 A
5487757 Truckai et al. Jan 1996 A
5496312 Klicek Mar 1996 A
5497774 Swartz et al. Mar 1996 A
5498248 Milder Mar 1996 A
5500012 Brucker et al. Mar 1996 A
5505730 Edwards Apr 1996 A
5514130 Baker May 1996 A
5516505 McDow May 1996 A
5520682 Baust et al. May 1996 A
5522870 Ben-Zion Jun 1996 A
5536267 Edwards et al. Jul 1996 A
5542928 Evans et al. Aug 1996 A
5545195 Lennox et al. Aug 1996 A
5545200 West et al. Aug 1996 A
5549661 Kordis et al. Aug 1996 A
5555883 Avitall Sep 1996 A
5558671 Yates Sep 1996 A
5560362 Sliwa, Jr. et al. Oct 1996 A
5562703 Desai Oct 1996 A
5562720 Stern et al. Oct 1996 A
5564440 Swartz et al. Oct 1996 A
5569241 Edwards Oct 1996 A
5569242 Lax et al. Oct 1996 A
5571088 Lennox et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573532 Chang et al. Nov 1996 A
5575766 Swartz et al. Nov 1996 A
5575788 Baker et al. Nov 1996 A
5575810 Swanson et al. Nov 1996 A
5578007 Imran Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5584872 LaFontaine et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5590657 Cain et al. Jan 1997 A
5595183 Swanson et al. Jan 1997 A
5605539 Buelna et al. Feb 1997 A
5607462 Imran Mar 1997 A
5617854 Munsif Apr 1997 A
5630837 Crowley May 1997 A
5634924 Turkel et al. Jun 1997 A
5637090 McGee et al. Jun 1997 A
5637110 Pennybacker et al. Jun 1997 A
5640995 Ockuly et al. Jun 1997 A
5643197 Brucker et al. Jul 1997 A
5653692 Masterson et al. Aug 1997 A
5656029 Imran et al. Aug 1997 A
5658278 Imran et al. Aug 1997 A
5660836 Knowlton Aug 1997 A
5671747 Connor Sep 1997 A
5673695 McGee et al. Oct 1997 A
5676662 Fleischhacker et al. Oct 1997 A
5676692 Sanghvi et al. Oct 1997 A
5676693 LaFontaine Oct 1997 A
5678550 Bassen et al. Oct 1997 A
5680860 Imran Oct 1997 A
5681278 Igo et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5683384 Gough et al. Nov 1997 A
5687723 Avitall Nov 1997 A
5687737 Branham et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5690611 Swartz et al. Nov 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697925 Taylor Dec 1997 A
5697927 Imran et al. Dec 1997 A
5697928 Walcott et al. Dec 1997 A
5713942 Stern Feb 1998 A
5716389 Walinsky et al. Feb 1998 A
5718241 Ben-Haim et al. Feb 1998 A
5718701 Shai et al. Feb 1998 A
5720775 Lanard Feb 1998 A
5722400 Ockuly et al. Mar 1998 A
5722402 Swanson et al. Mar 1998 A
5730074 Peter Mar 1998 A
5730127 Avitall Mar 1998 A
5730704 Avitall Mar 1998 A
5733280 Avitall Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5735290 Nelson et al. Apr 1998 A
5735846 Panescu et al. Apr 1998 A
5746739 Sutter May 1998 A
5755753 Knowlton May 1998 A
5755760 Maguire et al. May 1998 A
5769846 Edwards et al. Jun 1998 A
5782828 Chen et al. Jul 1998 A
5785705 Baker Jul 1998 A
5785706 Bednarek Jul 1998 A
5788636 Curley Aug 1998 A
5792140 Tu et al. Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5798960 Stevens et al. Aug 1998 A
5800413 Swartz et al. Sep 1998 A
5800428 Nelson et al. Sep 1998 A
5800482 Pomeranz et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5823956 Roth et al. Oct 1998 A
5827216 Igo et al. Oct 1998 A
5833703 Manushakian Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5840030 Ferek-Petric et al. Nov 1998 A
5844349 Oakley et al. Dec 1998 A
5846187 Wells et al. Dec 1998 A
5846191 Wells et al. Dec 1998 A
5849028 Chen Dec 1998 A
5855614 Stevens et al. Jan 1999 A
5860974 Abele Jan 1999 A
5871523 Fleischman et al. Feb 1999 A
5871525 Edwards et al. Feb 1999 A
5873845 Cline et al. Feb 1999 A
5876399 Chia et al. Mar 1999 A
5879295 Li et al. Mar 1999 A
5879296 Ockuly et al. Mar 1999 A
5881732 Sung et al. Mar 1999 A
5882346 Pomeranz et al. Mar 1999 A
5885278 Fleischman Mar 1999 A
5893848 Negus et al. Apr 1999 A
5895417 Pomeranz et al. Apr 1999 A
5897553 Mulier et al. Apr 1999 A
5897554 Chia et al. Apr 1999 A
5899898 Arless et al. May 1999 A
5899899 Arless et al. May 1999 A
5902289 Swartz et al. May 1999 A
5904711 Flom et al. May 1999 A
5906580 Kline-Schoder et al. May 1999 A
5906587 Zimmon May 1999 A
5906606 Chee et al. May 1999 A
5908029 Knudson et al. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5916214 Cosio et al. Jun 1999 A
5921924 Avitall Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5927284 Borst et al. Jul 1999 A
5928191 Houser et al. Jul 1999 A
5931810 Grabek Aug 1999 A
5931848 Saadat Aug 1999 A
5954661 Greenspon et al. Sep 1999 A
5967976 Larsen et al. Oct 1999 A
5971980 Sherman Oct 1999 A
5971983 Lesh Oct 1999 A
5993447 Blewett et al. Nov 1999 A
6007499 Martin et al. Dec 1999 A
6012457 Lesh Jan 2000 A
6016811 Knopp et al. Jan 2000 A
6017338 Brucker et al. Jan 2000 A
6030379 Panescu et al. Feb 2000 A
6042556 Beach et al. Mar 2000 A
6053912 Panescu et al. Apr 2000 A
6056745 Panescu et al. May 2000 A
6063081 Mulier May 2000 A
6071279 Whayne et al. Jun 2000 A
6088894 Oakley Jul 2000 A
6096037 Mulier Aug 2000 A
6099524 Lipson et al. Aug 2000 A
6113592 Taylor Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6120496 Whayne et al. Sep 2000 A
6142993 Whayne et al. Nov 2000 A
6142994 Swanson et al. Nov 2000 A
6152920 Thompson et al. Nov 2000 A
6161543 Cox et al. Dec 2000 A
6165174 Jacobs et al. Dec 2000 A
6217528 Koblish et al. Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6231518 Grabek et al. May 2001 B1
6235024 Tu May 2001 B1
6237605 Vaska et al. May 2001 B1
6238347 Nix et al. May 2001 B1
6238393 Mulier May 2001 B1
6241754 Swanson Jun 2001 B1
6245061 Panescu et al. Jun 2001 B1
6245064 Lesh et al. Jun 2001 B1
6245065 Panescu et al. Jun 2001 B1
6251092 Qin et al. Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6270471 Hechel et al. Aug 2001 B1
6293943 Panescu et al. Sep 2001 B1
6296619 Brisken et al. Oct 2001 B1
6302880 Schaer Oct 2001 B1
6302903 Mulier et al. Oct 2001 B1
6311692 Vaska et al. Nov 2001 B1
6312383 Lizzi et al. Nov 2001 B1
6314962 Vaska et al. Nov 2001 B1
6314963 Vaska et al. Nov 2001 B1
6315777 Comben Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6328736 Mulier Dec 2001 B1
6332881 Carner et al. Dec 2001 B1
6358248 Mulier Mar 2002 B1
6361531 Hissong Mar 2002 B1
6364876 Erb et al. Apr 2002 B1
6368275 Sliwa et al. Apr 2002 B1
6371955 Fuimaono et al. Apr 2002 B1
6383151 Diederich et al. May 2002 B1
6385472 Hall et al. May 2002 B1
6398792 O'Connor Jun 2002 B1
6409722 Hoey Jun 2002 B1
6413254 Hissong et al. Jul 2002 B1
6419648 Vitek et al. Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6430426 Avitall Aug 2002 B2
6440130 Mulier Aug 2002 B1
6443952 Mulier Sep 2002 B1
6447507 Bednarek et al. Sep 2002 B1
6451013 Bays et al. Sep 2002 B1
6461314 Pant et al. Oct 2002 B1
6461956 Patterson Oct 2002 B1
6464700 Koblish et al. Oct 2002 B1
6471697 Lesh Oct 2002 B1
6471698 Edwards et al. Oct 2002 B1
6474340 Vaska et al. Nov 2002 B1
6475216 Mulier Nov 2002 B2
6477396 Mest et al. Nov 2002 B1
6484727 Vaska et al. Nov 2002 B1
6488680 Francischelli Dec 2002 B1
6497705 Comben Dec 2002 B2
6502575 Jacobs et al. Jan 2003 B1
6514250 Jahns Feb 2003 B1
6527767 Wang et al. Mar 2003 B2
6537248 Mulier Mar 2003 B2
6537272 Hoey Mar 2003 B2
6558382 Jahns May 2003 B2
6584360 Francischelli Jun 2003 B2
6585732 Mulier et al. Jul 2003 B2
6595934 Hissong et al. Jul 2003 B1
6605084 Acker et al. Aug 2003 B2
6610055 Swanson et al. Aug 2003 B1
6610060 Mulier Aug 2003 B2
6613048 Mulier Sep 2003 B2
6623515 Mulier et al. Sep 2003 B2
6645199 Jenkins et al. Nov 2003 B1
6648883 Francischelli Nov 2003 B2
6656175 Francischelli Dec 2003 B2
6663627 Francischelli Dec 2003 B2
6692450 Coleman Feb 2004 B1
6695839 Sharkey et al. Feb 2004 B2
6699240 Francischelli Mar 2004 B2
6702811 Stewart et al. Mar 2004 B2
6706038 Francischelli Mar 2004 B2
6706039 Mulier Mar 2004 B2
6716211 Mulier Apr 2004 B2
6730082 Messing et al. May 2004 B2
6736810 Hoey May 2004 B2
6755827 Mulier Jun 2004 B2
6764487 Mulier et al. Jul 2004 B2
6773433 Stewart et al. Aug 2004 B2
6776780 Mulier Aug 2004 B2
6807968 Francischelli Oct 2004 B2
6827715 Francischelli Dec 2004 B2
6849073 Hoey Feb 2005 B2
6858028 Mulier Feb 2005 B2
6887238 Jahns May 2005 B2
6899711 Stewart et al. May 2005 B2
6911019 Mulier Jun 2005 B2
6916318 Francischelli Jul 2005 B2
6936046 Hissong Aug 2005 B2
6949097 Stewart et al. Sep 2005 B2
6949098 Mulier et al. Sep 2005 B2
6960205 Jahns Nov 2005 B2
6962589 Mulier Nov 2005 B2
6989010 Francischelli et al. Jan 2006 B2
7029470 Francischelli et al. Apr 2006 B2
7083620 Jahns et al. Aug 2006 B2
7094235 Francischelli Aug 2006 B2
7118566 Jahns Oct 2006 B2
7128740 Jacobs et al. Oct 2006 B2
7156845 Mulier et al. Jan 2007 B2
7166105 Mulier et al. Jan 2007 B2
7169144 Hoey et al. Jan 2007 B2
7247155 Hoey et al. Jul 2007 B2
7250048 Francischelli et al. Jul 2007 B2
7250051 Francischelli Jul 2007 B2
7261711 Mulier et al. Aug 2007 B2
7294143 Francischelli Nov 2007 B2
7309325 Mulier et al. Dec 2007 B2
7364579 Mulier et al. Apr 2008 B2
7422588 Mulier et al. Sep 2008 B2
20020032441 Ingle et al. Mar 2002 A1
20030045872 Jacobs Mar 2003 A1
20030144656 Ocel Jul 2003 A1
20030191462 Jacobs Oct 2003 A1
20030216724 Jahns Nov 2003 A1
20030216733 McClurken et al. Nov 2003 A1
20040015106 Coleman Jan 2004 A1
20040015219 Francischelli Jan 2004 A1
20040030331 Thomas et al. Feb 2004 A1
20040044340 Francischelli Mar 2004 A1
20040049179 Francischelli Mar 2004 A1
20040078069 Francischelli Apr 2004 A1
20040082948 Stewart et al. Apr 2004 A1
20040087940 Jahns May 2004 A1
20040092926 Hoey May 2004 A1
20040133251 Altschuler et al. Jul 2004 A1
20040138621 Jahns Jul 2004 A1
20040138656 Francischelli Jul 2004 A1
20040143260 Francischelli Jul 2004 A1
20040181214 Garabedian et al. Sep 2004 A1
20040186465 Francischelli Sep 2004 A1
20040215183 Hoey Oct 2004 A1
20040220560 Briscoe Nov 2004 A1
20040236322 Mulier Nov 2004 A1
20040267326 Ocel Dec 2004 A1
20050010095 Stewart et al. Jan 2005 A1
20050033280 Francischelli Feb 2005 A1
20050080411 Ouchi Apr 2005 A1
20050090815 Francischelli Apr 2005 A1
20050143729 Francischelli Jun 2005 A1
20050165392 Francischelli Jul 2005 A1
20050209564 Bonner Sep 2005 A1
20050256522 Francischelli et al. Nov 2005 A1
20050267454 Hissong Dec 2005 A1
20060009756 Francischelli Jan 2006 A1
20060009759 Christian Jan 2006 A1
20060015097 Mulier et al. Jan 2006 A1
20060052770 Mulier et al. Mar 2006 A1
20060074414 Mulier et al. Apr 2006 A1
20060079888 Mulier et al. Apr 2006 A1
20060142753 Francischelli et al. Jun 2006 A1
20060161149 Privitera et al. Jul 2006 A1
20060161151 Privitera et al. Jul 2006 A1
20060217701 Young et al. Sep 2006 A1
20070032786 Francischelli Feb 2007 A1
20070043397 Ocel et al. Feb 2007 A1
20070049923 Jahns Mar 2007 A1
20070093808 Mulier et al. Apr 2007 A1
20070118107 Francischelli et al. May 2007 A1
20070118114 Miller et al. May 2007 A1
20070208332 Mulier et al. Sep 2007 A1
20070270795 Francischelli et al. Nov 2007 A1
20070270799 Francischelli Nov 2007 A1
20070270800 Francischelli Nov 2007 A1
20080015563 Hoey et al. Jan 2008 A1
20080071271 Francischelli Mar 2008 A1
Foreign Referenced Citations (18)
Number Date Country
1007960 May 1957 DE
0370890 May 1990 EP
0499491 Aug 1992 EP
0500215 Aug 1992 EP
0500289 Aug 1992 EP
2235669 Jan 1975 FR
57-117843 Jul 1982 JP
7-51288 Feb 1995 JP
9003152 Apr 1990 WO
9006079 Jun 1990 WO
9410924 May 1994 WO
9410925 May 1994 WO
9411059 May 1994 WO
9426228 Nov 1994 WO
9505781 Mar 1995 WO
9509570 Apr 1995 WO
9517222 Jun 1995 WO
9607360 Mar 1996 WO
Related Publications (1)
Number Date Country
20080300593 A1 Dec 2008 US
Continuations (8)
Number Date Country
Parent 11635166 Dec 2006 US
Child 12189398 US
Parent 11230839 Aug 2005 US
Child 11635166 US
Parent 10883178 Jul 2004 US
Child 11230839 US
Parent 10411921 Apr 2003 US
Child 10883178 US
Parent 09955496 Sep 2001 US
Child 10411921 US
Parent 09580228 May 2000 US
Child 09955496 US
Parent 09236034 Jan 1999 US
Child 09580228 US
Parent 08556784 Nov 1995 US
Child 09236034 US
Continuation in Parts (1)
Number Date Country
Parent 08393082 Feb 1995 US
Child 08556784 US